SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Economic Modeling Considerations for Rare Diseases · Study

ReviewEconomic Modeling Considerations for Rare Diseases

Isobel V. Pearson2018

OA

Reviewbronze2018

Economic Modeling Considerations for Rare Diseases

Isobel V. Pearson · Ben Rothwell · Andrew Olaye

63 citations·0/0 files stored·Value in Health

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Health Systems, Economic Evaluations, Quality of Life Pharmaceutical Economics and Policy Statistical Methods in Clinical Trials

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 63 citations exist upstream.

References

2012Model Transparency and Validation 2012Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1 2016Assessing the Gold Standard — Lessons from the History of RCTs 2020Using Experts` Opinions Through Delphi Technique 2012Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7 2007Assessing the economic challenges posed by orphan drugs 2011Pricing and reimbursement of orphan drugs: the need for more transparency 2016Meta‐analysis of few small studies in orphan diseases

Cited by

2021How to Value Orphan Drugs? A Review of European Value Assessment Frameworks

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

2021How to Value Orphan Drugs? A Review of European Value Assessment Frameworksreview · 8 shared references 2018Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?review · 5 shared references 2018The European challenges of funding orphan medicinal productsarticle · 5 shared references 2017Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)article · 4 shared references 2016Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countriesreview · 4 shared references 2015AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Usersarticle · 3 shared references

Details

Year2018

Typereview

Published2018-04-17

VenueValue in Health

ISSN-L1098-3015

Languageen

Citations63

Files0 public / 0

ShelfHealth Systems, Economic Evaluations, Quality of Life

Identifiers

doi10.1016/j.jval.2018.02.008

openalex_workW2801849778

Links

Imported from OpenAlex (CC0) — nothing here is generated.